Gilead Sciences Inc (GILD : NASDAQ)
Common Stock
$30.49
USD
-122.18 (-80.03%)
Last updated: 2026-09-23
Follow GILD
GILD
Gilead Sciences Inc
WealthAwesomePerformance
1 Day
-0.85%
1 Week
+2.50%
1 Month
+3.74%
YTD
+21.34%
Key Statistics
Market Cap
$187.69B
52W High
$154.51
52W Low
$105.84
P/E Ratio
-
50 Day MA
$140.83
200 Day MA
$135.70
Beta
0.35
Dividend Yield
2.11%
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/23/2026 | $153.60 | $154.20 | $150.06 | $151.37 | $151.37 | 6,191,894 |
| 9/22/2026 | $150.65 | $153.28 | $148.65 | $152.67 | $152.67 | 5,082,660 |
| 9/21/2026 | $150.11 | $152.09 | $148.22 | $150.56 | $150.56 | 5,569,448 |
| 9/18/2026 | $150.56 | $153.23 | $149.57 | $150.11 | $150.11 | 16,412,100 |
| 9/17/2026 | $148.78 | $151.04 | $146.89 | $150.89 | $150.89 | 7,842,200 |
| 9/16/2026 | $146.58 | $149.30 | $146.12 | $147.68 | $147.68 | 5,187,900 |
| 9/15/2026 | $144.00 | $146.35 | $142.94 | $146.30 | $146.30 | 4,532,600 |
| 9/14/2026 | $144.26 | $146.75 | $143.71 | $146.41 | $145.59 | 4,919,900 |
| 9/11/2026 | $145.24 | $145.99 | $143.50 | $143.72 | $142.92 | 4,202,400 |
| 9/10/2026 | $145.07 | $145.91 | $143.67 | $144.81 | $144.00 | 6,019,300 |
Analyst Price Targets
Based on 30 analysts covering GILD · as of Sep 24, 2026
Wall Street analysts forecast GILD stock price to rise 420.3% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
US$158.65
+420.3% Upside
Previously US$158.15 on Sep 17, 2026
Current Price
US$30.49
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
23.8%
Annualized
90-Day Vol
27.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$180.96
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$160.65 | US$147.98 – US$174.41 |
| 60 trading days | US$170.51 | US$151.81 – US$191.51 |
| 90 trading days | US$180.96 | US$156.97 – US$208.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Financials
- Revenue (TTM)
- $30.46B
- EBITDA
- $14.60B
- Profit Margin
- -10.64%
- ROE (TTM)
- -20.68%
- EPS (Diluted)
- -2.63
- Book Value
- 9.53
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GILD.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BENF | Beneficient Class A Common Stock | $2.90 | +438.73% |
| JAGX | Jaguar Animal Health Inc | $8.91 | +233.71% |
| WHLR | Wheeler Real Estate Investment Trust, Inc. | $5.44 | +190.91% |
| VSA | TCTM Kids IT Education Inc. | $3.64 | +83.84% |
| ARTL | Artelo Biosciences Inc | $7.31 | +76.14% |
| BFRG | Bullfrog AI Holdings, Inc. Common Stock | $0.95 | +58.33% |
| VTGN | VistaGen Therapeutics Inc | $0.37 | +46.54% |
| IPDN | Professional Diversity Network Inc | $5.42 | +38.97% |
GILD.US news timeline
7 articles covering GILD.US, most recent first
Latest